GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellerophon Therapeutics Inc (OTCPK:BLPH) » Definitions » Goodwill

Bellerophon Therapeutics (Bellerophon Therapeutics) Goodwill : $0.00 Mil (As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Bellerophon Therapeutics Goodwill?

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Bellerophon Therapeutics's goodwill for the quarter that ended in Sep. 2023 was $0.00 Mil.


Bellerophon Therapeutics Goodwill Historical Data

The historical data trend for Bellerophon Therapeutics's Goodwill can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellerophon Therapeutics Goodwill Chart

Bellerophon Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Goodwill
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bellerophon Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Goodwill Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Bellerophon Therapeutics Goodwill Calculation

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.


Bellerophon Therapeutics  (OTCPK:BLPH) Goodwill Explanation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Bellerophon Therapeutics's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Goodwill-to-Asset (A: Dec. 2022 )=Goodwill/Total Assets
=0/7.935
=

Bellerophon Therapeutics's Goodwill-to-Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

Goodwill-to-Asset (Q: Sep. 2023 )=Goodwill/Total Assets
=0/4.979
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Bellerophon Therapeutics Goodwill Related Terms

Thank you for viewing the detailed overview of Bellerophon Therapeutics's Goodwill provided by GuruFocus.com. Please click on the following links to see related term pages.


Bellerophon Therapeutics (Bellerophon Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
184 Liberty Corner Road, Suite 302, Warren, NJ, USA, 07059
Bellerophon Therapeutics Inc is a clinical-stage therapeutics company. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. It develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. The company's products are aimed at the treatment of different kinds of pulmonary hypertension.
Executives
Puissance Life Science Opportunities Fund Vi 10 percent owner 950 THIRD AVENUE, FL 25, NEW YORK NY 10022
Naseem Amin director 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Mary Ann Cloyd director 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Theodore T Wang director C/O PUISSANCE CAPITAL MANAGEMENT LP, 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Scott P Bruder director C/O BELLEROPHON THERAPEUTICS, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Crispin Teufel director 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Puissance Capital Fund (gp) Llc 10 percent owner 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Parag Suresh Shah officer: VP of Business Operations C/O BELLEROPHON THERAPEUTICS, INC., 184 LIBERTY CORNER ROAD, SUITE 302, NEW JERSEY NJ 07059
Martin Dekker officer: See Remarks 53 FRONTAGE ROAD, SUITE 301, PERRYVILLE III CORPORATE PARK, HAMPTON NJ 08827
Peter Fernandes officer: See Remarks PERRYVILLE III CORPORATE PARK, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Bobae Kim officer: VP Reg. Affairs & Quality 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Nicholas Laccona officer: Controller, (PFO & PAO) 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Steven B Klinsky 10 percent owner C/O NEW MOUNTAIN CAPITAL, L.L.C., 1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019
New Mountain Capital, L.l.c. 10 percent owner 1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019
New Mountain Investments Ii, Llc 10 percent owner 787 SEVENTH AVENUE, 49TH FLOOR, NEW YORK NY 10019

Bellerophon Therapeutics (Bellerophon Therapeutics) Headlines

From GuruFocus